Regalbuto C, Belfiore A, Giuffrida D, Ippolito A, Motta R M, Sava L
Cattedra di Endocrinologia, University of Catania, Ospedale Garibaldi, Italy.
J Endocrinol Invest. 1991 Sep;14(8):675-8. doi: 10.1007/BF03347892.
Ultrasound scanning is an accurate and objective method to assess thyroid volume; therefore it is useful to evaluate the effectiveness of L-thyroxine treatment in reducing goiter size, especially in children where clinical evaluation is inaccurate. In this prospectic study we evaluated the effectiveness of one-year L-thyroxine treatment in a group of children with nontoxic diffuse goiter coming from an area with low iodine intake. We examined 11 children (7 females, 4 males), age range 9-14 years. At clinical examination, 6 patients had a goiter classified Ia (according to WHO criteria), 4 had a class Ib and only 1 had a class II goiter. In order to achieve an accurate goiter evaluation, the thyroid volume was determined by ultrasonic scanning with a 5 MHz linear probe before and after treatment. Patients were given a dose of L-thyroxine (1.5-2.0 micrograms/kg/die) in order to significantly reduce serum TSH levels (from 1.8 +/- 0.6 to 0.8 +/- 0.5 mU/l, mean +/- SD). Patients were reexamined at 12 months of therapy and again at 10 months after therapy withdrawal. A significant reduction of the goiter volume (greater than 20%) was obtained in 6/11 (54%) patients, although serum TSH levels were fully suppressed only in one. The mean goiter size reduction in "responders" was -31.2 +/- 9.3% (m +/- SE). After therapy withdrawal goiter size increased in the majority of cases (in 4/11, greater than 20%). Our study demonstrates that L-thyroxine treatment is effective in reducing goiter size in the majority of children with a diffuse goiter.(ABSTRACT TRUNCATED AT 250 WORDS)
超声扫描是评估甲状腺体积的一种准确且客观的方法;因此,它对于评估左甲状腺素治疗在缩小甲状腺肿大小方面的有效性很有用,尤其是在临床评估不准确的儿童中。在这项前瞻性研究中,我们评估了一组来自低碘摄入地区的非毒性弥漫性甲状腺肿儿童接受为期一年的左甲状腺素治疗的有效性。我们检查了11名儿童(7名女性,4名男性),年龄在9至14岁之间。临床检查时,6例患者的甲状腺肿根据世界卫生组织标准分类为Ia级,4例为Ib级,只有1例为II级甲状腺肿。为了实现准确的甲状腺肿评估,在治疗前后使用5兆赫线性探头通过超声扫描测定甲状腺体积。给予患者左甲状腺素剂量(1.5 - 2.0微克/千克/天)以显著降低血清促甲状腺激素水平(从1.8±0.6降至0.8±0.5毫国际单位/升,平均值±标准差)。在治疗12个月时对患者进行复查,并在停药10个月后再次复查。11例患者中有6例(54%)甲状腺肿体积显著缩小(大于20%),尽管只有1例患者的血清促甲状腺激素水平得到完全抑制。“有反应者”的甲状腺肿平均缩小尺寸为-31.2±9.3%(平均值±标准误)。停药后,大多数病例(11例中有4例,大于20%)甲状腺肿大小增加。我们的研究表明,左甲状腺素治疗对大多数弥漫性甲状腺肿儿童缩小甲状腺肿大小有效。(摘要截断于250字)